



Disclosures

Personal Commercial (9)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------|---|--------------------------|---------------|
| <i>Self</i> | | | |
| 89bio | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Amarin | Speaker's Bureau | Significant (>= \$5,000) | Prevention |
| Amgen Inc. | Speaker's Bureau | Modest (< \$5,000) | Prevention |
| Amryt | Speaker's Bureau | Modest (< \$5,000) | Prevention |
| Dalcor | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Esperion | Speaker's Bureau | Significant (>= \$5,000) | Prevention |
| Esperion | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Immunovant | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Kowa | Research/Research Grants ‡ PROMINENT | Modest (< \$5,000) | Prevention |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (4)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|--|---|--------------------------|---------------|
| <i>Self</i> | | | |
| Atherometabolism Institute ‡ Pfizer Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Atherometabolism Institute ‡ Novartis Corporation | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Atherometabolism Institute ‡ Immunovant | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Utah Lipid Center ‡ Regeneron | Research/Research Grants ‡ Pediatric trial of evinacumab | Significant (>= \$5,000) | Prevention |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

| Year | Case Title | Represented | Description | Compensation |
|-------------|--|--|--|--------------------------|
| <i>Self</i> | | | | |
| 2022 | Icosapent ethyl in CVD risk reduction | Plaintiff | Patent issues over use of icosapent ethyl to prevent CV death in mixed dyslipidemia | Significant (>= \$5,000) |
| 2020 | New onset diabetes with atorvastatin use | Plaintiff ‡ Heard, Robins, Cloud and Black, LLP | class-action lawsuit against Pfizer regarding failure to disclose risk of new-onset diabetes with atorvastatin use | Significant (>= \$5,000) |

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 3/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 3/19/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.